- Home
- NGNE vs AACB Comparison
NGNE vs AACB Comparison
Compare NGNE & AACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- AACB
- Stock Information
- Founded
- NGNE 2003
- AACB 2024
- Country
- NGNE United States
- AACB United States
- Employees
- NGNE N/A
- AACB N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- AACB
- Sector
- NGNE Health Care
- AACB
- Exchange
- NGNE Nasdaq
- AACB Nasdaq
- Market Cap
- NGNE 325.3M
- AACB 298.1M
- IPO Year
- NGNE N/A
- AACB 2025
- Fundamental
- Price
- NGNE $20.51
- AACB $10.13
- Analyst Decision
- NGNE Strong Buy
- AACB
- Analyst Count
- NGNE 7
- AACB 0
- Target Price
- NGNE $41.86
- AACB N/A
- AVG Volume (30 Days)
- NGNE 123.0K
- AACB 230.0
- Earning Date
- NGNE 08-11-2025
- AACB 01-01-0001
- Dividend Yield
- NGNE N/A
- AACB N/A
- EPS Growth
- NGNE N/A
- AACB N/A
- EPS
- NGNE N/A
- AACB N/A
- Revenue
- NGNE N/A
- AACB N/A
- Revenue This Year
- NGNE N/A
- AACB N/A
- Revenue Next Year
- NGNE N/A
- AACB N/A
- P/E Ratio
- NGNE N/A
- AACB N/A
- Revenue Growth
- NGNE N/A
- AACB N/A
- 52 Week Low
- NGNE $6.88
- AACB $10.00
- 52 Week High
- NGNE $74.49
- AACB $11.35
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- AACB N/A
- Support Level
- NGNE $18.94
- AACB N/A
- Resistance Level
- NGNE $21.59
- AACB N/A
- Average True Range (ATR)
- NGNE 1.40
- AACB 0.00
- MACD
- NGNE -0.26
- AACB 0.00
- Stochastic Oscillator
- NGNE 32.30
- AACB 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About AACB Artius II Acquisition Inc. Class A Ordinary Shares
Artius II Acquisition Inc is a blank check company.